Literature DB >> 11380397

Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide.

K Lotfi1, E Månsson, J Chandra, Y Wang, D Xu, E Knaust, T Spasokoukotskaja, E Liliemark, S Eriksson, F Albertioni.   

Abstract

Cross-resistance between different classes of anti-neoplastic agents can jeopardize successful combination cancer chemotherapy. In this study, we observed an unexpected cross-resistance between the podophyllotoxine derivative etoposide (VP) and the nucleoside analogue cladribine (CdA) in CCRF-CEM cells developed for resistance to VP. The resistant cells also displayed 14- and twofold resistance to cytarabine (ara-C) and gemcitabine respectively. Closer analysis of these cells showed that they contained lower amounts of topoisomerase (topo) IIalpha (P < 0.001) and beta protein (P < 0.026), formed substantially lower amounts of the topo II-DNA complex, and had a markedly decreased level of Fas (CD95/APO-1)-ligand mRNA expression. Interestingly, Fas expression in the resistant cells did not differ from that in the parental cell line. No differences were observed in the accumulation/efflux of daunorubicin or in the gene expressions of P-glycoprotein, multidrug resistance-associated protein and the lung resistance-related protein. The activity of deoxycytidine kinase (dCK), responsible for activation of CdA and ara-C, was the same for resistant and wild-type cells. However, there was an increase in the activity of the cytosolic 5'-nucleotidases (5'-NT), responsible for deactivation of nucleotides, amounting to 206% (P < 0.001) for the high Km and 134% (P < 0.331) for the low Km 5'-NT in resistant cells. The high Km 5'-NT is probably responsible for the decreased amount of the active metabolite CdA 5'-triphosphate [40% decreased (P < 0.045)], as well as for other purine ribonucleosides and deoxyribonucleosides triphosphates in the resistant cells. In contrast, a significantly higher deoxycytidine triphosphate (dCTP) level (167%, P < 0.001) was observed in the resistant cells. Thus, this study suggests that the major cause of resistance to the nucleoside analogues CdA and ara-C in cells selected for resistance to VP is a result of metabolic alterations producing increased activity of 5'-NT and higher dCTP levels. Furthermore, these results indicate that there is a common factor in the regulation of nucleotide-degrading enzymes and DNA topoisomerases, which may be altered in cross-resistant cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380397     DOI: 10.1046/j.1365-2141.2001.02751.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.

Authors:  V Mey; E Giovannetti; F De Braud; S Nannizzi; G Curigliano; F Verweij; O De Cobelli; S Pece; M Del Tacca; R Danesi
Journal:  Br J Cancer       Date:  2006-07-25       Impact factor: 7.640

2.  Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.

Authors:  Ho Kyung Seo; Kyung-Ohk Ahn; Nae-Rae Jung; Ji-Sun Shin; Weon Seo Park; Kang Hyun Lee; Sang-Jin Lee; Kyung-Chae Jeong
Journal:  Oncotarget       Date:  2014-01-30

3.  5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.

Authors:  Francesca Toffalorio; Mariacarmela Santarpia; Davide Radice; Christopher Adrian Jaramillo; Gianluca Spitaleri; Michela Manzotti; Chiara Catania; Lars Petter Jordheim; Giuseppe Pelosi; Godefridus J Peters; Carmelo Tibaldi; Niccola Funel; Lorenzo Spaggiari; Filippo de Braud; Tommaso De Pas; Elisa Giovannetti
Journal:  Oncotarget       Date:  2018-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.